Navigation Links
Know your enemy
Date:4/25/2014

rain when Parkinson's disease occurs and develops is absolutely necessary, not only for the prevention and treatment of symptoms, but also for possibly developing a cure one day.

However, getting to know the enemy is no easy task when it comes to understanding Parkinson's disease. The more we find out, the more complex the image becomes.

We already know that the disease as well as other neurological disorders arises because some protein structures in the body start clumping together. They stack themselves on top of each other and gradually form what are known as fibrils long, thin needle-shaped structures. From a biochemical point of view, this is quite a boring process because the protein structures simply pile themselves on top of each other and in principle can continue to do so forever.

It is far more interesting to look at the intermediate stages leading up to the aggregation. It turns out here that when the proteins form fibrils, a kind of intermediate aggregation process also takes place to form oligomers, which consist of a small number of protein molecules that clump together. It is presumably the oligomers that kill the nerve cells and cause the symptoms of Parkinson's disease. So oligomers are the enemy we want to control.

Ground-breaking new knowledge about the enemy

In their two studies, the researchers from Aarhus University, the University of Southern Denmark and the University of Cambridge provide the most well-documented description of oligomers to date. Until now, the general perception was that oligomers were precursors of the fibrils. As it turns out, however, it is rather the antagonists or competitors of the fibrils that are the precursors, and these are capable of slowing down the formation of fibrils.

The researchers discovered that there are different kinds of oligomers. If we look at the size, there are two types that are quite intimately connected. A somewhat small oligomer that
'/>"/>

Contact: Daniel Otzen
dao@inano.au.dk
45-20-72-52-38
Aarhus University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Newly identified small-RNA pathway defends genome against the enemy within
2. How safe is the enemy of a citrus-threatening pest?
3. Influenza study: Meet virus new enemy
4. Lack of energy an enemy to antibiotic-resistant microbes
5. The hungry caterpillar: Beware your enemys enemys enemy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... , This release is available in German ... now be produced inexpensively and in large quantities. This means ... 225 million malaria patients in developing countries at an affordable ... Interfaces in Potsdam and the Freie Universitt Berlin have developed ...
... Can a one-size-fits all approach really work? The world ... In the west it is already widespread and it ... change in the lifestyles of recent generations., "Fat, Fate and ... tackled by focusing solely on adult lifestyles and asks the ...
... evolve the ability to grow beyond the tissues in ... tumor cells -- are tethered to scaffolding that helps ... University of Helsinki, Finland, and from UCSF have identified ... them to further misbehave. The protein, they ...
Cached Biology News:Anti-malaria drug synthesized with the help of oxygen and light 2Anti-malaria drug synthesized with the help of oxygen and light 3'Fat, Fate and Disease' 2Some breast cancer spread may be triggered by a protein, study shows 2Some breast cancer spread may be triggered by a protein, study shows 3
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... , July 24, 2014 Lyfebulb, ... Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North ... or "the Company"), announced a collaboration to increase ... last night at an event attended by more ... parties. Lyfebulb is a health and wellness company ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... Each year, thousands of Amgen staff generously devote their ... charitable organizations. To recognize these exceptional efforts, the Amgen Foundation ... Excellence in Volunteering Awards. The Awards ... Rico who are making a difference in the communities ...
... 2011 Generex Biotechnology Corporation ( www.generex.com ) ... status of the previously announced spinout of its ... The Company is in the midst ... transaction opportunities, including both shell companies and operating ...
... 2011 EvaluatePharma Ltd, the research company, is ...  With a team based in Tokyo, EvaluatePharma Japan KK will ... Japan. "Japan is a very important market for ... major customers from a distance, but it is now time ...
Cached Biology Technology:Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits 2Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits 3Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4EvaluatePharma Japan KK - Now Open for Business in Tokyo 2
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Black 96 Well Plate EB, RE Bottom...
...
...
Biology Products: